The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030, predicts Roots Analysis
Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.”

The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
 A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
 Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
 An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
 An analysis of the expansions related to continuous manufacturing, which have been established since 2013
 An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
 A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
 An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
 Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
 A review of the companies offering modular facilities / modular cleanrooms
 A case study of the companies offering technologies / equipment
 A case study on the roadmap for the adoption of continuous manufacturing technique
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Purpose of Manufacturing
 In-House
 Contract service
 Scale of Operation
 Commercial
 Preclinical / Clinical
 Type of Continuous Manufacturing related Service
 API Manufacturing
 End Product manufacturing
 Type of Drug Molecule
 Biologic
 Small Molecule
 Type of dosage form
 Solid
 Liquid
 Key Geographical Regions
 North America
 Europe
 Asia Pacific

 Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
 Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
 Nick Thomson, Senior Director Chemical Research and Development, Pfizer
 Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
 Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
 Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde



Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis

The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030, predicts Roots Analysis Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.” The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing  Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market  An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013  An analysis of the expansions related to continuous manufacturing, which have been established since 2013  An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).  A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019  An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019  Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.  A review of the companies offering modular facilities / modular cleanrooms  A case study of the companies offering technologies / equipment  A case study on the roadmap for the adoption of continuous manufacturing technique  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Purpose of Manufacturing  In-House  Contract service  Scale of Operation  Commercial  Preclinical / Clinical  Type of Continuous Manufacturing related Service  API Manufacturing  End Product manufacturing  Type of Drug Molecule  Biologic  Small Molecule  Type of dosage form  Solid  Liquid  Key Geographical Regions  North America  Europe  Asia Pacific  Transcripts of interviews held with the following senior level representatives of stakeholder companies  Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies  Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals  Nick Thomson, Senior Director Chemical Research and Development, Pfizer  Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences  Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)  Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis
WWW.ROOTSANALYSIS.COM
Continuous Manufacturing Market (Small Molecules and Biologics) | Industry Analysis | Market Size | 2030
Market research report on pharmaceutical continuous manufacturing; with a focus on current landscape, key players and future growth opportunities
0 Comments 0 Shares